Zobrazeno 1 - 10
of 706
pro vyhledávání: '"V. Patterson"'
Autor:
Abigail V. Sharrock, Jeff S. Mumm, Elsie M. Williams, Narimantas Čėnas, Jeff B. Smaill, Adam V. Patterson, David F. Ackerley, Gintautas Bagdžiūnas, Vickery L. Arcus
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6593 (2024)
Bacterial nitroreductase enzymes capable of activating imaging probes and prodrugs are valuable tools for gene-directed enzyme prodrug therapies and targeted cell ablation models. We recently engineered a nitroreductase (E. coli NfsB F70A/F108Y) for
Externí odkaz:
https://doaj.org/article/35db6809fd4042d9882cc7c017640035
Autor:
Jorie M. Butler, Bryan Gibson, Olga V. Patterson, Laura J. Damschroder, Corrinne H. Halls, Daniel W. Denhalter, Matthew H. Samore, Haojia Li, Yue Zhang, Scott L. DuVall
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background In this study we sought to explore the possibility of using patient centered care (PCC) documentation as a measure of the delivery of PCC in a health system. Methods We first selected 6 VA medical centers based on their scores for
Externí odkaz:
https://doaj.org/article/277fbea85c594c5ea7371edc83cb2f16
Autor:
Victoria Jackson-Patel, Emily Liu, Matthew R. Bull, Amir Ashoorzadeh, Gib Bogle, Anna Wolfram, Kevin O. Hicks, Jeff B. Smaill, Adam V. Patterson
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Hypoxia-activated prodrugs are bioactivated in oxygen-deficient tumour regions and represent a novel strategy to exploit this pharmacological sanctuary for therapeutic gain. The approach relies on the selective metabolism of the prodrug under patholo
Externí odkaz:
https://doaj.org/article/c34ba5238adc4eb49a0ab52ce8b13172
Autor:
April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 20 (2021)
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sac
Externí odkaz:
https://doaj.org/article/b3e4d96313984c458e4300e40728aa41
Autor:
Mehul Trivedi, Suha Godil, Joshua Demb, Ashley Earles, Ranier Bustamante, Olga V. Patterson, Andrew J. Gawron, Tonya Kaltenbach, Sumana Mahata, Lin Liu, Samir Gupta
Publikováno v:
Clinical Gastroenterology and Hepatology. 21:1637-1645
Traditional serrated adenomas (TSAs) may confer increased risk for colorectal cancer (CRC). Our objective with this study was to examine clinical characteristics and long-term outcomes associated with TSA diagnosis.We conducted a retrospective cohort
Autor:
Marsha A. Wilcox, Danielle Coppola, Nicole Bailey, Andrew Wilson, Aaron W. C. Kamauu, Patrick R. Alba, Olga V. Patterson, Benjamin Viernes, Daniel W. Denhalter, Ira D. Solomon, Scott L. DuVall
Publikováno v:
Neurology and Therapy, Vol 8, Iss 1, Pp 95-108 (2019)
Abstract Introduction Janssen received reports of needle detachments for Risperdal® CONSTA® and, in response, redesigned the kit. Objective The study objective was to estimate the rate of Risperdal® CONSTA® needle detachments prior to and after t
Externí odkaz:
https://doaj.org/article/65e87f8a25ff46749125fdfec58674b4
Autor:
Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 15, Iss , Pp 62-69 (2019)
Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of tumors, which are an important cause of treatment resistance to conventional therapies. Despite promising preclinical and clinical phase I and II results, the
Externí odkaz:
https://doaj.org/article/75c6748e20a543519df6ae43fdf0f2f0
Autor:
Amir Ashoorzadeh, Alexandra M. Mowday, Christopher P. Guise, Shevan Silva, Matthew R. Bull, Maria R. Abbattista, Janine N. Copp, Elsie M. Williams, David F. Ackerley, Adam V. Patterson, Jeff B. Smaill
Publikováno v:
Pharmaceuticals, Vol 15, Iss 2, p 185 (2022)
PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in pre-clinical GDEPT studies, yet off-target human al
Externí odkaz:
https://doaj.org/article/9dcd35635dfd4a64b8e3fee16b54111f
Autor:
Maria R. Abbattista, Amir Ashoorzadeh, Christopher P. Guise, Alexandra M. Mowday, Rituparna Mittra, Shevan Silva, Kevin O. Hicks, Matthew R. Bull, Victoria Jackson-Patel, Xiaojing Lin, Gareth A. Prosser, Neil K. Lambie, Gabi U. Dachs, David F. Ackerley, Jeff B. Smaill, Adam V. Patterson
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1231 (2021)
PR-104 is a phosphate ester pre-prodrug that is converted in vivo to its cognate alcohol, PR-104A, a latent alkylator which forms potent cytotoxins upon bioreduction. Hypoxia selectivity results from one-electron nitro reduction of PR-104A, in which
Externí odkaz:
https://doaj.org/article/b19c86e2af6c49538c7e81a3e7b91af6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.